作者回顾性分析1978～1982年间瑞典最北部三个地区无选择性慢性淋巴细胞白血病(CLL)122例病人并随访至1989年11月,平均随访期105个月。男:女为2.2:1,平均年龄71岁。根据Binet分期,A期61例,B期29例和C期32例。常规体检发现21例,因患另一种疾病检查而发现46例,因CLL相关症状就诊发现55例。治疗方法如单用强的松、单一化疗药物或加强的松、联合化疗等,对生存期无显著影响。治疗组80例中数生存期为62个月,对照未治疗组42例为35个月,P=0.18,无统计学差异。全部病人中数自然生存期为51个月。分期和其它预后因素如外周血血红蛋白、淋巴细胞数及血小板数 The authors retrospectively analyzed 122 patients with selective chronic lymphocytic leukemia (CLL) in the northernmost three regions of Sweden from 1978 to 1982 and followed up until November 1989 with an average follow-up of 105 months. Male: Female 2.2: 1, average age 71 years old. According to the Binet staging, 61 were in stage A, 29 in stage B and 32 in stage C. Routine physical examination found 21 cases, due to another disease check found 46 cases, found in 55 cases due to CLL-related symptoms. Treatment methods such as prednisone alone, single chemotherapy drugs or enhanced pine, combined chemotherapy, no significant impact on survival. The median survival time was 80 in the treatment group and 62 months in the untreated group, and 35 months in the untreated group (P = 0.18). There was no significant difference. The median overall survival for all patients was 51 months. Staging and other prognostic factors such as peripheral blood hemoglobin, lymphocyte count, and platelet count